Logo

GRDN

Guardian Pharmacy Services, Inc.

GRDN

Guardian Pharmacy Services, Inc. • NYSE
$29.28 ▼ -0.20% (-0.06)
Market Cap $1.85 B
52w High $37.43
52w Low $17.78
Dividend Yield 0%
P/E 43.06
Volume 96.73K
Outstanding Shares 63.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $377.427M ▲ $58.367M ▲ $9.818M ▲ 2.601% ▼ $0.16 ▲ $23.607M ▲
Q2-2025 $344.334M ▲ $55.566M ▲ $9.03M ▼ 2.622% ▼ $0.15 $18.248M ▼
Q1-2025 $329.308M ▼ $51.344M ▲ $9.448M ▼ 2.869% ▼ $0.15 ▼ $18.543M ▼
Q4-2024 $338.569M ▲ $50.349M ▼ $11.943M ▲ 3.527% ▲ $0.2 ▲ $21.795M ▲
Q3-2024 $314.393M $165.491M $-112.64M -35.828% $-2 $-99.621M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $36.487M ▲ $390.037M ▲ $194.54M ▲ $183.756M ▲
Q2-2025 $18.817M ▲ $356.334M ▲ $176.663M ▲ $169.563M ▲
Q1-2025 $13.999M ▲ $333.998M ▲ $170.781M ▼ $156.087M ▲
Q4-2024 $4.66M ▼ $320.81M ▼ $170.834M ▼ $142.671M ▲
Q3-2024 $37.221M $348.027M $214.131M $127.567M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $9.593M ▲ $0 ▼ $0 ▲ $0 ▲ $0 ▼ $0 ▼
Q2-2025 $8.827M ▼ $19.936M ▲ $-13.004M ▼ $-2.114M ▲ $4.818M ▼ $15.63M ▲
Q1-2025 $9.448M ▼ $17.55M ▼ $-5.545M ▲ $-2.666M ▲ $9.339M ▲ $11.745M ▼
Q4-2024 $11.943M ▲ $22.337M ▲ $-6.624M ▲ $-48.274M ▼ $-32.561M ▼ $17.836M ▲
Q3-2024 $-105.817M $-2.164M $-7.081M $44.928M $35.683M $-7.291M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Corporate Segment
Corporate Segment
 $330.00M ▲$340.00M ▲$380.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past five years, showing that demand for Guardian’s services is increasing and that its niche strategy is gaining traction. Profitability, however, is mixed: the company had a string of modest profits, but the most recent year swung into a noticeable loss at the operating and net income level. This suggests either rising costs, integration or technology investments, or pricing pressure that has outpaced revenue growth. Overall, the business looks like a classic distribution model with thin margins, where small changes in cost or reimbursement can have an outsized impact on earnings.

Balance Sheet

Balance Sheet The balance sheet appears relatively lean, with a modest asset base and only limited use of debt, which helps keep financial risk contained. The recent emergence of a positive equity position points to a stronger capital footing than in prior years, which may reflect recapitalization or retained earnings from earlier periods. The most concerning feature is the very low reported cash, which implies that the company relies heavily on ongoing cash generation and credit lines to operate. This setup can work as long as cash flows remain stable, but it leaves less room for error during downturns or if reimbursement tightens.

Cash Flow

Cash Flow Despite the recent accounting loss, cash generation from day‑to‑day operations has been consistently positive and fairly stable over several years. Free cash flow has also remained positive, even after funding ongoing investments in technology and infrastructure, which appear relatively modest but gradually increasing. This pattern indicates that the underlying business is cash‑generative and that non‑cash items or one‑time factors may be weighing on reported earnings. Strong and steady cash flow is a key offset to the thin margins and low cash balance on the balance sheet.

Competitive Edge

Competitive Edge Guardian occupies a focused niche in long‑term care pharmacy, especially in assisted living and behavioral health, where medication needs are complex and often underserved. Its model of locally empowered pharmacies backed by national technology and support is a clear differentiator, combining high‑touch service with scale advantages. Proprietary analytics tools, deep integration with facility systems, and hands‑on clinical support create switching costs and help build sticky relationships with facilities. The main competitive risks come from larger national pharmacy players, reimbursement and regulatory changes in long‑term care, and the challenge of integrating acquisitions while preserving local culture and service quality.

Innovation and R&D

Innovation and R&D Innovation is centered on software, data analytics, and workflow tools rather than traditional lab‑style R&D. The GuardianShield and Compass platforms, along with third‑party tech partnerships, show a consistent push to use data to manage medication safety, spending, and operations more intelligently. The company is openly exploring predictive analytics and artificial intelligence to flag high‑risk residents and optimize drug regimens, which could deepen its clinical value if executed well. The key question is how effectively Guardian can continue to upgrade its technology stack and roll out new tools across diverse local pharmacies without disrupting service or inflating costs too much.

Summary

Guardian combines a growing top line and consistently positive cash flow with a specialized position in long‑term care pharmacy, supported by proprietary technology and a distinctive local‑autonomy model. The most recent move into losses highlights that profitability is not yet firmly secured and that margins remain sensitive to cost and reimbursement dynamics. Financially, the company appears conservatively leveraged but runs with a thin cash cushion, which raises sensitivity to any disruption in cash flows. Strategically, its depth in assisted living and behavioral health, along with strong data and integration capabilities, provides a meaningful moat, while ongoing tech and AI initiatives offer further upside potential. Future performance will largely depend on restoring and sustaining profitability, managing growth and acquisitions carefully, and successfully turning continued tech investment into durable operational and clinical advantages.

NEWS

November 10, 2025 · 4:05 PM UTC

Guardian Pharmacy Services Reports Third Quarter 2025 Financial Results; Raises Full-Year Guidance

Read more

October 28, 2025 · 4:30 PM UTC

Guardian Pharmacy Services, Inc. to Participate in Upcoming Stephens Investment Conference

Read more

October 14, 2025 · 4:47 PM UTC

Guardian Pharmacy Services Announces Filing of S-3 Shelf Registration Statement and Lock-up Agreements with Pre-IPO Holders of Class A Common Stock

Read more

October 6, 2025 · 8:30 AM UTC

Guardian Pharmacy Services, Inc. to Report Third Quarter 2025 Financial Results and Host Conference Call

Read more

September 11, 2025 · 8:30 AM UTC

Guardian Pharmacy Services, Inc. to Participate in Upcoming Jefferies Healthcare Services Investor Conference

Read more